Drug Profile
T7T7 gene delivery systems - Indevus Pharmaceuticals
Latest Information Update: 29 Oct 1999
Price :
$50
*
At a glance
- Originator Ohio University
- Class
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Solid tumours
Most Recent Events
- 29 Oct 1999 Discontinued-Preclinical for Solid tumours in USA (Injection)
- 31 Mar 1998 New profile
- 31 Mar 1998 Preclinical development for Solid tumours in USA (Injection)